나노엔텍

039860KOSDAQ

62.3 / 100

Reference Date: 2026-09-08

Financial Score18.0 / 40

News Sentiment18.3 / 25

Momentum14.0 / 20

Disclosure12.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Rose 8.2% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

NanoEntek develops, manufactures, and sells in vitro diagnostic medical devices and life science experiment equipment based on the Lab-On-a-Chip (LOC) platform. The company leverages its core Bio-MEMS technology, integrating microfluidics and nanotechnology, to enable applications in cancer diagnostics, cell counting, and other fields. It operates a U.S. sales subsidiary and a B2B healthcare service arm, expanding its global market presence.

Number of Employees

141people

Average Salary

53.2M KRW

Score Calculation Basis

Detailed Financial Score

PER

87.98Industry Average 15.000.0Point

5.9x industry avg (risky)

PBR

1.73Industry Average 1.202.5Point

Higher than industry avg (caution)

ROE

1.92Industry Average 8.001.0Point

Well below industry avg

Debt Ratio

1.76Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20256.5 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲19.3% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲102.6% (2-year basis)

ROE Trend

1.0 / 4

Avg ROE 0.3% (improving, 3yr)

Detailed News Sentiment

3 totalPositive 2Neutral 1Negative 0Average Sentiment Score 73.3

Positive
나노엔텍, 50억원 규모 자사주 매입…"전량 소각 추진"
나노엔텍의 자사주 매입 결정으로 주주 가치 증대와 기업 신뢰도 향상 기대.
Positive
정찬일 나노엔텍 대표 "美 성호르몬 진단시장 본격 공략"
나노엔텍 대표의 미국 시장 진출 전략 발표로 인해 긍정적인 시장 반응이 예상되며, 플랫폼 인지도 상승이 기대됩니다.
Neutral
“노화 개선 넘어 건강 피부 맞춤 관리” 뷰티업계 경쟁
뷰티업계의 롱제비티 트렌드에 대한 언급이 있으나, 나노엔텍의 직접적인 영향은 제한적임.

Detailed Momentum

52-week position3.0Point

52w lower range (23%)

Current 4,135Won52-week high 7,67052-week low 3,030

1-month return5.0Point

1m +8.25% (rising)

Volume trend6.0Point

Volume increasing

Detailed Disclosure

2 totalPositive 1Neutral 1Negative 0

Positive주요사항보고서(자기주식취득신탁계약체결결정)2026-09-01
Neutral반기보고서 (2026.06)2026-08-14